Cognition Therapeutics, Inc.

NasdaqGM:CGTX Voorraadrapport

Marktkapitalisatie: US$18.9m

Cognition Therapeutics Beheer

Beheer criteriumcontroles 1/4

Cognition Therapeutics' CEO is Lisa Ricciardi, appointed in Mar 2020, has a tenure of 4.67 years. total yearly compensation is $1.66M, comprised of 35.3% salary and 64.7% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $34.70K. The average tenure of the management team and the board of directors is 1.7 years and 3.7 years respectively.

Belangrijke informatie

Lisa Ricciardi

Algemeen directeur

US$1.7m

Totale compensatie

Percentage CEO-salaris35.3%
Dienstverband CEO4.7yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn1.7yrs
Gemiddelde ambtstermijn bestuur3.7yrs

Recente managementupdates

Recent updates

Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Sep 06
Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease

Jul 31

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

May 22
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Apr 18

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Nov 30
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Aug 15
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Mar 17
Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

Sep 27

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Aug 12
We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

Aug 05

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Mar 19
We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Analyse CEO-vergoeding

Hoe is Lisa Ricciardi's beloning veranderd ten opzichte van Cognition Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$31m

Mar 31 2024n/an/a

-US$29m

Dec 31 2023US$2mUS$587k

-US$26m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$24m

Dec 31 2022US$1mUS$550k

-US$21m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$22m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$11mUS$409k

-US$16m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$1mUS$287k

-US$12m

Compensatie versus markt: Lisa's total compensation ($USD1.66M) is above average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: Lisa's compensation has increased whilst the company is unprofitable.

CEO

Lisa Ricciardi (64 yo)

4.7yrs

Tenure

US$1,660,686

Compensatie

Ms. Lisa R. Ricciardi serves as Chief Executive Officer and President at Cognition Therapeutics, Inc. since March 2020 and serves as Director since March 2019. She serves as a Consultant of Davita RX. Ms....

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Lisa Ricciardi
CEO, President & Director4.7yrsUS$1.66m0.18%
$ 34.7k
John Doyle
Chief Financial Officer1.5yrsUS$737.26k0.047%
$ 8.8k
Anthony Caggiano
Chief Medical Officer and Head of R&D5.6yrsUS$972.12k0.047%
$ 8.8k
Steven Weissman
VP & Head of CMC1.3yrsgeen gegevensgeen gegevens
Anita Cornet
Head of Qualityless than a yeargeen gegevensgeen gegevens
Bobby Horn
Corporate Controller1.8yrsgeen gegevensgeen gegevens

1.7yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: CGTX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Lisa Ricciardi
CEO, President & Director5.7yrsUS$1.66m0.18%
$ 34.7k
Ellen Richstone
Independent Director3yrsUS$83.61k0.040%
$ 7.5k
Jack Khattar
Independent Chairman of the Board4.3yrsUS$145.11k0.015%
$ 2.8k
Harry LeVine
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Susan Catalano
Member of Scientific Advisory Board2.8yrsgeen gegevensgeen gegevens
Cynthia Lemere
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Michael Grundman
Member of Medical Advisory Board2.8yrsgeen gegevensgeen gegevens
Aaron Glenn Fletcher
Independent Director9.3yrsUS$74.61k0.015%
$ 2.8k
John Cirrito
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Rolf Craven
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Alison Goate
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Robert Mach
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

3.7yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: CGTX's board of directors are considered experienced (3.7 years average tenure).